Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Urologic Neoplasms 1Urogenital Neoplasms 1Tuberculosis 1Neoplasms 1Hematuria 1Fever 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Sunitinib 3Specimen Handling 3Paclitaxel 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Drug Therapy 3Carboplatin 3Biopsy 3Abiraterone Acetate 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Suspensions 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Administration, Intravesical × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔